SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc.…
Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY® (diroximel fumarate) consistent with previous assessmentsPatient-reported outcomes…
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing…
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to placeboBiogen is currently enrolling…
CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing…
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained reductions in neurofilament, a marker of…
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high rates of persistence and adherence…